University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Eric J. Small, MD

Eric J. Small, MD

Professor of Medicine; Urology; and Chief, Department of Medicine/Division of Hematology/Oncology, UCSF
Deputy Director and Chief Scientific Officer; Program Leader, Prostate Cancer Program, UCSF Helen Diller Family Comprehensive Cancer Center
Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research; Stanford W. Ascherman and Norman R. Ascherman Endowed Chair, UCSF

Cancer Center Program Memberships

Prostate Cancer

Education

Stanford University, Stanford, CA, BS, 1980, Biology
Case Western Reserve University of Medicine, Cleveland, Ohio, MD, 1985, Medicine
Beth Israel Hospital, Boston, MA, Internship and Residency, 1988, Internal Medicine
University of California San Francisco, CA, Fellowship, 1991, Hematology/Oncology


Professional Experience

  • 1982-1983
    Pathology Fellowship, Department of Pathology, Case Western Reserve Univ., Cleveland, OH
  • 1985-1988
    Internal Medicine Internship and Residency Training Program, Beth Israel Hospital, Boston, MA
  • 1988-1989
    Clinical Fellow, Cancer Research Institute, UCSF, San Francisco, CA
  • 1989-1991
    Research Fellow, Cancer Research Institute, (Dr. Marc Shuman) UCSF, San Francisco, CA
  • 1991-1997
    Assistant Clinical Professor of Medicine, UCSF, San Francisco, CA
  • 1991-present
    Head, Urologic Medical Oncology, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 1996-present
    Co-Director, Urologic Oncology Program, UCSF, San Francisco, CA
  • 1997-2001
    Associate Clinical Professor of Medicine and Urology, UCSF, San Francisco, CA
  • 1999-present
    Chair, Genitourinary Committee, Cancer and Leukemia Group B (CALGB)
  • 2001-present
    Professor in Residence of Medicine and Urology, UCSF, San Francisco, CA
  • 2007-2009
    Interim Chief, Division of Hematology and Oncology, UCSF, San Francisco, CA
  • 2007-present
    Director, Investigational Trials Resource, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2009-present
    Chief, Division of Hematology/Oncology, UCSF, San Francisco, CA
  • 2009-present
    Deputy Director and Director of Clinical Sciences, UCSF Helen Diller Family Comprehensive Cancer Center

Honors & Awards

  • 1978
    Biomedical Research Grant, The Jackson Laboratory, Bar Harbour, ME
  • 1980
    NIH Research Support Grant, Case Western Reserve University, Cleveland, OH
  • 1984
    Alpha Omega Alpha Honor Medical Society
  • 1997
    Prostate Cancer Foundation Therapy Consortium
  • 2006-present
    Stanford W. and Norman R. Ascherman Endowed Chair

Selected Publications

  1. Smith MR, Yu MK, Small EJ. Apalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 06 28; 378(26):2542.
    View on PubMed
  2. Antonarakis ES, Small EJ, Petrylak D, Quinn DI, Kibel AS, Chang N, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association With Overall Survival. Clin Cancer Res. 2018 Jun 01.
    View on PubMed
  3. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 04 12; 378(15):1408-1418.
    View on PubMed
  4. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clin Genitourin Cancer. 2017 Dec 27.
    View on PubMed
  5. Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer. 2018 Apr 01; 124(7):1383-1390.
    View on PubMed
  6. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12).
    View on PubMed
  7. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017 Sep 19; 7(1):77.
    View on PubMed
  8. Small EJ. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017 09 11; 32(3):392.
    View on PubMed
  9. Small EJ. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017 07 10; 32(1):6-8.
    View on PubMed
  10. Aggarwal RR, Feng FY, Small EJ. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74.
    View on PubMed
  11. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 Sep; 15(9):1221-1229.
    View on PubMed
  12. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 Dec; 15(6):733-741.e1.
    View on PubMed
  13. Anantharaman A, Small EJ. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017 07; 17(7):625-633.
    View on PubMed
  14. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. J Vasc Interv Radiol. 2017 Aug; 28(8):1073-1081.e1.
    View on PubMed
  15. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int. 2018 Apr; 121(4):534-539.
    View on PubMed
  16. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 Dec; 58(12):1956-1961.
    View on PubMed
  17. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005.
    View on PubMed
  18. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 07; 72(1):10-13.
    View on PubMed
  19. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 2017 Sep 22; 8(42):71447-71455.
    View on PubMed
  20. Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017 07; 72(1):34-42.
    View on PubMed

Go to UCSF Profiles, powered by CTSI